Minneapolis, MN Clinical Trials Report — April 2026

April 2026 brings important deadlines for Minneapolis residents interested in clinical research, with 64 trials slated to conclude enrollment within the next 90 days. For those without specific health conditions, 12 of these urgent studies are still actively seeking healthy volunteers, offering a valuable chance to contribute to medical science before enrollment closes. Individuals considering participation should explore these options promptly.

New Opportunities in Minneapolis Research

This month, Minneapolis saw the launch of 9 new clinical trials, a slight increase from the 8 trials that opened in March 2026. These new studies contribute to the city's robust research landscape, which currently features 887 clinical trials recruiting across 258 research facilities.

Several notable new trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches, including significant studies from major sponsors:

• Novo Nordisk A/S is sponsoring NCT07533175, "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight." This Phase 3 trial aims to enroll 630 participants to evaluate the safety and effectiveness of a new weekly injectable treatment for individuals with excess body weight and type 2 diabetes.
• The Minneapolis Veterans Affairs Medical Center is leading NCT07541599, "Reaching Rural Veterans: Applying Mind-Body Skills for Pain Using a Whole Health Telehealth Intervention - UH3." This study, targeting 500 participants, focuses on providing Veterans with mind-body tools through telehealth to help them manage chronic pain more effectively.
• Seattle Institute for Biomedical and Clinical Research is behind NCT07507435, "Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults." This research seeks 480 participants to explore how pharmacist-led interventions can improve lung health and reduce pneumonia risk in people with HIV.
• Temple University is sponsoring NCT07505121, "Comparing the Impact of Peer Support vs. Staff-Delivered Transportation Interventions for Young Adults With Intellectual and Developmental Disabilities." This study will involve 325 participants to compare the effectiveness of a travel training program delivered by peer supporters versus staff for young adults with intellectual and developmental disabilities.
• Eloxx Pharmaceuticals, Inc. is conducting NCT07523581, "EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety." This Phase 2, randomized, double-blind, placebo-controlled study is designed for 24 patients aged 12 and older with Alport Syndrome, evaluating the efficacy and safety of exaluren.

The new trials cover a range of conditions, including advanced solid tumor, alport syndrome (autosomal recessive and x-linked), autism spectrum disorder, chronic pain, dementia, developmental disability, diabetes mellitus, HIV, and inhaled corticosteroid use. Among the types of new trials, 3 are drug trials, 3 are categorized as "OTHER," 2 are behavioral interventions, and 1 is a device trial.

Upcoming Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, cardiovascular issues, and metabolic conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Ovarian cancer (2 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Acute limb ischemia (1 trial)
• Acute myeloid leukemia (1 trial)
• Adolescent obesity (1 trial)
• Advanced lung non-small cell carcinoma (1 trial)
• Advanced solid tumor (1 trial)
• Advanced NSCLC (1 trial)
• Age-related macular degeneration (1 trial)
• ALS-frontotemporal dementia (1 trial)

Leading Research Facilities in Minneapolis

Minneapolis is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Minnesota (285 trials)
• Abbott-Northwestern Hospital (86 trials)
• Hennepin County Medical Center (75 trials)
• University of Minnesota/Masonic Cancer Center (44 trials)
• Health Partners Inc (39 trials)
• Minneapolis Heart Institute Foundation (27 trials)
• Children's Hospitals and Clinics of Minnesota - Minneapolis (26 trials)
• Minneapolis VA Health Care System, Minneapolis, MN (22 trials)
• Research Site (17 trials)
• University of Minnesota Medical Center (14 trials)
• Minneapolis Heart Institute (14 trials)
• Masonic Cancer Center (13 trials)

The University of Minnesota and its affiliated centers lead the research efforts, offering a broad spectrum of studies across many medical fields. Facilities like Abbott-Northwestern Hospital, Hennepin County Medical Center, and the Minneapolis Heart Institute Foundation also contribute significantly to the city's research capacity.

Opportunities for Healthy Volunteers

While none of the 9 new trials launched this month are specifically recruiting healthy volunteers, there remain ample opportunities for individuals without specific health conditions to contribute to medical research in Minneapolis. A total of 99 trials are currently recruiting healthy participants in the city, including the 12 studies mentioned earlier that are closing within 90 days. These trials offer a chance to support medical advancements without requiring a specific diagnosis.

Expanding Your Search: Nearby Options

While Minneapolis offers a wide array of clinical trial opportunities, individuals may also find options in other communities within Minnesota. Cities with active trials include Rochester (7 trials), Saint Paul (2 trials), Dilworth (1 trial), Maple Grove (1 trial), and Richfield (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 9 new trials launched recently, 2 include children and 8 include older adults, ensuring that various age groups have opportunities to contribute to medical science. Academic institutions, notably the University of Minnesota and its Masonic Cancer Center, continue to play a vital role in Minneapolis's research ecosystem, sponsoring 4 of the new trials. Federal and industry sponsors, including the Minneapolis Veterans Affairs Medical Center, Eloxx Pharmaceuticals, Inc., Seattle Institute for Biomedical and Clinical Research, Temple University, and Novo Nordisk A/S, are also driving significant research efforts.

As spring progresses, Minneapolis's research community will continue to focus on advancing medical knowledge, with ongoing enrollment in these diverse trials and the exploration of new therapeutic strategies.